Managing diabetic nephropathy: Recent studies

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 2, 2006, Pages 111-116

  Lit, Yiming Z ^a   Meyer, Timothy ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Chronic kidney disease; Diabetic nephropathy; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; AVOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; GLIBENCLAMIDE; INDAPAMIDE; PIOGLITAZONE; PIRFENIDONE; RAMIPRIL; ROSIGLITAZONE; SPIRONOLACTONE; SULODEXIDE; TRANDOLAPRIL; UNCLASSIFIED DRUG; VALSARTAN; VERAPAMIL; VOGLIBOSE;

ALBUMINURIA; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; HUMAN; HYPERKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DIABETIC NEPHROPATHIES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33646790842     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000214768.21911.62     Document Type: Review

References (44)

1. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951. This is one of the larger trials evaluating the renoprotective effect of calcium channel blockers as compared to ACE-Is in diabetic nephropathy. The results support the notion that calcium antagonists are not as effective as ACE-Is in renoprotection.
2. So WY, Ozaki R, Chan NN, et al. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients. Hypertension 2004; 44:294-299.
3. Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328:495.
4. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
5. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
6. Fioretto P, Solini A. Antihypertensive treatment and multifactorial approach for renal protection in diabetes. J Am Soc Nephrol 2005; 16 (Suppl 1):S18-S21.
7. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-1961. This was the first long-term study that directly compared renal outcomes of ACE-I to ARB in type 2 diabetic patients with early nephropathy.
8. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58:762-769.
9. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329:828. This is one of the more comprehensive systematic reviews of published data on comparison between ACE-I and ARB in terms of renal outcomes and mortality.
10. Andersen S, Rossing P, Juhl TR, et al. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002; 17:1413-1418.
11. Laverman GD, Henning RH, de Jong PE, et al. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001; 38:1381-1384.
12. Palla R, Panichi V, Finato V, et al. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994; 14:35-43.
13. Laverman GD, Andersen S, Rossing P, et al. Renoprotection with and without blood pressure reduction. Kidney Int Suppl 2005; 94:S54-S59.
14. Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and micro-albuminuria. Kidney Int 2005; 68:1190-1198.
15. Jacobsen P, Rossing K, Parving HH. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Curr Opin Nephrol Hypertens 2004; 13:319-324.
16. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004; 109:2492-2499.
17. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67:799-812.
18. Fujisawa T, Ikegami H, Ono M, et al. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am J Hypertens 2005; 18:13-17.
19. Cetinkaya R, Odabas AR, Selcuk Y. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes. Int J Clin Pract 2004; 58:432-435.
20. Jacobsen P, Parving HH. Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy. Kidney Int Suppl 2004; 92:S108-S110.
21. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124.
22. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
23. Pitt B, Zannad F, Remme WJ, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
24. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16 (9 Pt 1):781-788.
25. Sato A, Hayashi K, Naruse M, Saruta T, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41:64-68.
26. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18:44-49.
27. Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 2005; 28:2106-2112.
28. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543-551.
29. Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16:474-481.
30. Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22:1613-1622. This was one of the few available large studies evaluating the renoprotective effect of a diuretic.
31. Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens 2004; 13:155-161.
32. Perez-Maraver M, Carrera MJ, Micalo T, et al. Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment. Diabetes Res Clin Pract 2005; 70:13-19.
33. Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 2005; 68:285-292.
34. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004; 15:2801-2815.
35. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004; 53:1382-1386.
36. Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54:2206-2211.
37. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24:32-40. This was the first randomized controlled trial evaluating the renal outcomes of an AGEs formation inhibitor.
38. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393.
39. Joss N, Ferguson C, Brown C, et al. Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM 2004; 97:219-227. This prospective randomized trial illustrated the importance of a multifactorial approach and frequent follow-up in managing patients with diabetic nephropathy.
40. Leung WY, So WY, Tong PC, et al. The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant 2004; 19:2519-2525.
41. Rachmani R, Slavachevski I, Berla M, et al. Teaching and motivating patients to control their risk factors retards progression of cardiovascular as well as microvascular sequelae of Type 2 diabetes mellitus: a randomized prospective 8 years follow-up study. Diabet Med 2005; 22:410-414.
42. Gambaro G, Skrha J, Ceriello A. Glycosaminoglycan therapy for long-term diabetic complications? Diabetologia 1998; 41:975-979.
43. Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13:1615-1625.
44. Sugimoto KI, Fujimori A, Yuyama H, et al. Renal protective effect of YM598, a selective endothelin type A receptor antagonist. J Cardiovasc Pharmacol 2004; 44:S451-S454.